Latest Targeted therapy Stories
Phase III data for lenvatinib to be presented at ASCO WOODCLIFF LAKE, N.J., May 31, 2014 /PRNewswire/ -- Eisai Inc.
- Results from Phase I study of investigational oncology compound ABT-414 in patients with recurrent or unresectable glioblastoma multiforme, an aggressive type of brain cancer NORTH CHICAGO,
Tozaride Targeted Therapy Shows Tumor Reduction in Animal Model Somerville, Massachusetts (PRWEB) May 28, 2014 Andarix Pharmaceuticals, a clinical stage
Strategic dealmaker to advance Epic's leading circulating tumor cell (CTC) technology as a rapid and non-invasive platform for on-label, marketed companion diagnostics SAN DIEGO, May
Offers Potential New Therapy for Difficult-to-Treat Triple Negative Breast Cancer Philadelphia, PA (PRWEB) May 22, 2014 A study from the Department of
RnRMarketResearch.com offers "Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Novel HER-2 Positive Therapies Provide Diversified Treatment Options" research report in its
RnRMarketResearch.com adds "Ovarian Cancer Therapeutics in Major Developed Markets to 2020 - Late-Stage Pipeline Focuses on Improved Progression Free-Surival and Targeted Therapies" to its store. DALLAS,
First-in-class DOT1L Inhibitor in Clinical Development as Potential Personalized Therapeutic for Patients with Genetically Defined Acute Leukemias CAMBRIDGE, Mass., May 7, 2014 /PRNewswire/
Improvements in Key Efficacy Endpoints, Especially Overall Survival, are Pivotal Drivers for Prescribing, According to a New Report from Decision Resources Group BURLINGTON, Mass., April 29,
- Investigators to Present Clinical Trial Findings Evaluating Compounds in Multiple Tumor Types NORTH CHICAGO, Ill., April 23, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that
- A transitional zone between two communities containing the characteristic species of each.